Navigation Links
Breast Cancer Survivors and Patients Encouraged to Have Medical History Readily Available
Date:10/14/2009

ST. PETERSBURG, Fla., Oct. 14 /PRNewswire/ -- In the United States, a woman is diagnosed with breast cancer every three minutes, according to the American Cancer Society. Except for skin cancers, breast cancer is the most frequently diagnosed cancer among woman.

To help fight this disease, eMed-ID, the world's first emergency medical information device franchise, will donate $10 for every pink Personal Health Records (PHR) wristband sold to raise awareness during Breast Cancer Awareness Month. This pink wristband, as well as other optional styles, contains a USB device that has an individual's personal health history, medications taken, allergies, etc. eMed-ID's proprietary device is designed to expedite emergency responders' treatment of a patient who may not be able to communicate their personal medical information. It also helps consolidate health records and make them accessible to healthcare providers when needed.

"Individuals with breast cancer, as well as survivors of breast cancer, find themselves seeing numerous physicians and managing multiple medications and courses of treatment throughout their illness and beyond," said Lonnie Helgerson, CEO, eMed-ID Franchising, LLC. "As a result, we believe strongly that this group of individuals should have their personal health records consolidated and with them on e-Med-ID's PHR device in case of emergency or other circumstances that require medical history at the ready."

The eMed-ID package is $69.95 and includes the PHR USB device, four eMed-ID caregiver cards, two eMed-ID In Case of Emergency (I.C.E.) refrigerator cards and a bound report. In addition, eMed-ID is the only medical identification product that also provides customers with an optional legally-binding healthcare surrogate, HIPAA release and living will. The company also partners with the "Silver Alert" program, modeled after "Amber Alert," to help protect an increasing number of citizens with cognitive impairments. The pink wristband is just one option. Others include blue wristbands, credit cards and keychains.

"We are honored to join the fight on breast cancer and contribute a portion of the sales of our popular pink wristbands to breast cancer research," said Helgerson. "We've built the eMed-ID business to provide local communities, including people of all ages, with medical services and products that improve the quality of healthcare and save lives. This is just another way to become involved in the health care community and help individuals and families manage their own health."

Consumers can purchase the eMed-ID pink wristband, as well as other products, through eMed-ID's franchise network in cities located throughout the United States. To find your eMed-ID representative, visit www.emed-id.com/find.htm or call 1-866-607-0411.

For those interested in starting their own business, eMed-ID represents an ideal franchise opportunity given the current economic conditions by providing interested franchisees a low-cost of entry. The company is offering candidates the opportunity with a total investment of less than $10,000. Three-year term financing is available to qualified candidates for approximately $38 a week.

Area Representative opportunities are available starting at $29,950 to those interested in recruiting franchisees and owning a minimum protected territory of 200,000 residents. In addition, the franchise provides Veterans a $2,450 discount and a three percent reduction on financing interest.

About eMed-ID

Headquartered in St. Petersburg, FL, eMed-ID is the world's first emergency medical device franchise currently with 22 franchisees operating in several states including Florida, Indiana, Texas, Oregon, Arizona, North Carolina and Montana. The home-based, low cost franchise offers consumers a suite of emergency medical devices to protect their family and friends. For additional product or franchising information, please call 866.607.0411 or log onto www.eMed-ID.com.

    Media Contact:
    Kim Ryan
    Fish Consulting
    770.932.0695
    kryan@fish-consulting.com

SOURCE eMed-ID


'/>"/>
SOURCE eMed-ID
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
7. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
8. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
11. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... According to a new market research report "Life Science Analytics ... (Software, Service), Delivery (On premise, Cloud), End user (Pharmaceutical, Biotechnology, Medical ... is expected to reach USD 24.73 Billion by 2021 from USD ... forecast period. Continue Reading ... ...
(Date:1/20/2017)... Research and Markets has announced the addition of the ... Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic Panel, Liver Panel, Renal Panel, ... report to their offering. ... The global clinical laboratory testing market is expected to ... solutions on the grounds of maximum efficiency and minimum error is ...
(Date:1/20/2017)... 20, 2017  Palladian Health, a leading provider ... launch of an opioid management program which assists ... and helps stem the growing tide of dependence ... treat chronic non-cancer pain (back pain, neck pain, ... lack of evidence regarding long-term effectiveness. ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... January 21, 2017 , ... Seamild, the largest manufacturer of oats in ... its owner and founder. As Oat is recognized globally as one of the healthiest ... as he believes it is a move to sow the seed of good karma. ...
(Date:1/21/2017)... ... January 21, 2017 , ... Santa Rosa Orthopaedics (SRO) is ... at 167 Lynch Creek Way. The Petaluma office features three comfortable patient exam ... rehabilitation services and on-site x-ray services. Two multi-specialist orthopaedic surgeons Dr. Neema ...
(Date:1/20/2017)... ... ... A new partnership between Goodwill® and Roadie, Inc. aims to make it easier ... couches to dressers and bicycles. Roadie — the national on-the-way delivery network — will ... through February 28th. , “January is an exciting time when resolutions are made ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Bionic Sports ... all walks of life, announced it had a successful January ECRM Trade Show in ... in the United States, which allows it to provide its products to all clients ...
(Date:1/20/2017)... raton florida (PRWEB) , ... January 20, 2017 , ... ... at the Dana Farber Cancer Institute. For Betsy, the clinical trial has been ... her cancer has not worsened. , Betsy Brauser was diagnosed with ovarian cancer ...
Breaking Medicine News(10 mins):